Sofinnova Partners, a European venture capital firm specializing in Life Sciences, announced today the launch of MD Start III, which closed above its original target of €40 million. With this new medtech acceleration fund, Sofinnova Partners continues to reinforce its coverage across the Life Sciences sector, with funds operated by dedicated teams investing from seed to late stage.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,